Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2013 Feb;39(1):27-43. doi: 10.1016/j.ctrv.2012.03.007. Epub 2012 Apr 19.

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.

Author information

  • 1University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1862, USA.


Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.

Copyright © 2012 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk